{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-051191","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.469102+00:00","generated_at":"2026-05-28T23:53:05.285025+00:00","sec_items":["8.01"],"event_type":"other","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Telomir-1 shows copper-binding ability; Wilson's disease program advanced","bullets":["Preclinical studies show Telomir-1 strongly binds copper, targeting Wilson's disease caused by copper accumulation.","Company plans IND/INAD submission by Q4 2025, with clinical trials expected in 2026.","Telomir-1 also interacts with essential ions, potentially improving on current Wilson's treatments.","Telomir is advancing preclinical studies in Wilson's disease while exploring other copper-related conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-051191","json":"https://secwatch.observer/filing/0001493152-24-051191.json","markdown":"https://secwatch.observer/filing/0001493152-24-051191.md","text":"https://secwatch.observer/filing/0001493152-24-051191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224051191/0001493152-24-051191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224051191/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:53:05.285025+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}